Childhood and adolescent non-Hodgkin lymphoma: New insights in biology and critical challenges for the future

被引:47
作者
Cairo, MS
Raetz, E
Lim, MS
Davenport, V
Perkins, SL
机构
[1] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Childrens Hosp New York Presbyterian, Div Pediat Hematol & Blood & Marrow Transplantat, New York, NY 10032 USA
[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Leukemia Lymphoma Myeloma Program, New York, NY 10032 USA
[3] Columbia Univ, Dept Pediat Med & Pathol, New York, NY 10032 USA
[4] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[5] Univ Utah Hlth Sci, Dept Pathol, Salt Lake City, UT USA
关键词
biology; challenges; childhood; future; NHL;
D O I
10.1002/pbc.20342
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma. With systematic improvements in therapy over recent decades, the vast majority of children with NHL of all subtypes are now cured. The similarities and differences between adult and childhood presentations of disease, and whether or not some subtypes of NHL and leukemia are the same or different disease entities, are interesting questions that will be addressed with advances in our understanding of the molecular and genetic bases of these diseases. As is the case with other pediatric malignancies, growing emphasis is now being placed on the development of less toxic, targeted therapeutic approaches, and this review highlights some of the biological discoveries that will potentially open these avenues.
引用
收藏
页码:753 / 769
页数:17
相关论文
共 160 条
[1]  
ABROMOWITCH M, 2000, P ASCO
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]   Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma [J].
Amin, HM ;
McDonnell, TJ ;
Ma, YP ;
Lin, Q ;
Fujio, Y ;
Kunisada, K ;
Leventaki, V ;
Das, P ;
Rassidakis, GZ ;
Cutler, C ;
Medeiros, LJ ;
Lai, R .
ONCOGENE, 2004, 23 (32) :5426-5434
[4]   Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma [J].
Amin, HM ;
Medeiros, LJ ;
Ma, Y ;
Feretzaki, M ;
Das, P ;
Leventaki, V ;
Rassidakis, GZ ;
O'Connor, SL ;
McDonnell, TJ ;
Lai, R .
ONCOGENE, 2003, 22 (35) :5399-5407
[5]  
[Anonymous], WHO CLASSIFICATION T
[6]  
Asselin B, 2001, P AN M AM SOC CLIN, V20, P1464
[7]  
BAER R, 1993, SEMIN CANCER BIOL, V4, P341
[8]   Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway [J].
Bai, RY ;
Tao, OY ;
Miething, C ;
Morris, SW ;
Peschel, C ;
Duyster, J .
BLOOD, 2000, 96 (13) :4319-4327
[9]   The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression:: Implications for a role of BCL6 in the down-regulation of apoptosis [J].
Baron, BW ;
Anastasi, J ;
Thirman, MJ ;
Furukawa, Y ;
Fears, S ;
Kim, DC ;
Simone, F ;
Birkenbach, M ;
Montag, A ;
Sadhu, A ;
Zeleznik-Le, N ;
McKeithan, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) :2860-2865
[10]   Leukemia- and lymphoma-associated genetic aberrations in healthy individuals [J].
Bäsecke, J ;
Griesinger, F ;
Trümper, L ;
Brittinger, G .
ANNALS OF HEMATOLOGY, 2002, 81 (02) :64-75